A Study of Estrogen and Progesterone Cytosol Receptor Concentration in Benign and Malignant Ovarian Tumors and A Review of Malignant Ovarian Tumors Treated with Medroxy‐Progesterone Acetate

Publisher Website
Google Scholar
Abstract
ER and PR were assayed in 13 malignant and 20 benign ovarian tumors of different histologic types. ER was detectable in 67% and PR in 40% of the malignant tumors, compared with 35 and 45% in the benign tumors, respectively. The ER concentration was somewhat higher in the malignant lesions but there was no difference in the PR level.A retrospective review of 39 primary ovarian tumors of different pathologic stages and classes, treated postoperatively with medroxyprogesterone acetate (MPA, Depo‐Provera, Upjohn) and in most cases Melphalan, showed a high Karnofsky performance index and good complete and partial response rates. The need for a prospective, controlled study of the role of MPA treatment of malignant ovarian tumors is evident.